Among synthetic cannabinoid compounds, the CB1 inverse agonist pyrazole derivative rimonabant (SR14176A) produced by Sanofi-Aventis reached the market in Europe (as Acompliat®) for the treatment of obesity and related metabolic risk factors. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.